Search clinical trials for: CX-188

Total 3159 results

CytomX Therapeutics

Withdrawn

PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors

Solid Tumor, Adult

United States
Cylene Pharmaceuticals

Unknown

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
CytomX Therapeutics

Completed

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Neoplasms | Breast Cancer | Breast Neoplasms | Breast Neoplasms, Triple-Negative | Breast Neoplasms, Hormone Receptor Positive/HER2 Negative

United States, Spain, Korea, Republic of
CytomX Therapeutics

Recruiting

First In Human Study of CX-2051 in Advanced Solid Tumors

Solid Tumor, Adult

United States
Cylene Pharmaceuticals

Withdrawn

Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

B-Cell Chronic Lymphocytic Leukemia

United States
Senhwa Biosciences, Inc.

Active, not recruiting

Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

Carcinoma, Basal Cell

United States
London Health Sciences Centre
Pacific Edge Limited

Unknown

The Cxbladder Rule-out of Recurrent Urothelial Carcinoma

Bladder Cancer

Canada
Cylene Pharmaceuticals

Terminated

Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas

Lymphoma | Advanced Solid Tumors

United States
Cylene Pharmaceuticals

Completed

Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

Lymphoma | Advanced Solid Tumors

United States
Senhwa Biosciences, Inc.

Recruiting

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Advanced Solid Tumor

United States, Canada
Senhwa Biosciences, Inc.

Completed

A Study of Silmitasertib (CX-4945) in Healthy Subject

COVID-19

Taiwan
University of Arizona
Senhwa Biosciences, Inc.

Terminated

Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19) (CX4945)

Coronavirus

United States
Cylene Pharmaceuticals

Completed

Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Neuroendocrine Tumors | Carcinoid Tumor

United States
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI); American Lebanese Syrian Associated Charities...

Suspended

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

Medulloblastoma, Childhood

United States
Mayo Clinic
Blue Earth Diagnostics, Inc

Recruiting

18F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain

Metastatic Intracranial Malignant Neoplasm | Recurrent Intracranial Neoplasm

United States
Cylene Pharmaceuticals

Unknown

Dose-escalation Study of Oral CX-4945

Breast Cancer | Multiple Myeloma | Advanced Solid Tumors | Inflammatory Breast Cancer | Castleman's Disease

United States
Elixir Medical Corporation

Completed

Elixir Medical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - Cx Registry

Coronary Artery Disease

Belgium, Brazil
University of Modena and Reggio Emilia
University of Florence

Unknown

Tips Underdilatation in Patients With Cirrhosis

Cirrhosis

Italy
Senhwa Biosciences, Inc.

Not yet recruiting

Phase II, Double Blind, Randomized Trial of CX-4945 in Viral Community Acquired Pneumonia

Community-acquired Pneumonia | Influenza With Pneumonia | SARS-CoV-2 -Associated Pneumonia

Taiwan
GE Healthcare
National Cancer Institute (NCI)

Terminated

GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer

Prostate Cancer

United States
Puerta de Hierro University Hospital
Nutrition and Food Science Area, Faculty of Pharmacy, University of Valencia and other collaborators

Unknown

Effect of β-cryptoxanthin (β-Cx), Plant Sterols and Galactooligosaccharides on Systemic and Gastrointestinal Markers

Hypercholesterolemia | Osteoporosis | Postmenopausal Disorder
CytomX Therapeutics

Recruiting

A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors

Solid Tumors

United States
CytomX Therapeutics

Terminated

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

Breast Cancer | Head and Neck Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Solid Tumor, Adult

United States, Spain, Netherlands, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease

Metastatic Head and Neck Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma in Cervical Lymph Node

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery

Glioblastoma

United States
University Health Network, Toronto

Completed

Cervical Ca PROs in Clinical Practice

Cervical Cancer | Radiation Therapy

Canada
Merck Sharp & Dohme LLC

Completed

[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment
Chris Recknor, MD

Completed

Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

Covid19

United States
Jazz Pharmaceuticals

Completed

CX-8998 for Absence Seizures (T-WAVE)

Epilepsy

United States
Massachusetts General Hospital
Cedars-Sinai Medical Center; ALS Association; The Methodist Hospital Research...

Completed

Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis (TRACK-ALS)

Amyotrophic Lateral Sclerosis (ALS)

United States
Centre for Addiction and Mental Health

Completed

Transcranial Direct Current Stimulation (tDCS) in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

Canada
Jazz Pharmaceuticals

Completed

A Phase 2 RCT Study of CX-8998 for Essential Tremor

Essential Tremor

United States
Jazz Pharmaceuticals

Withdrawn

A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease

Parkinson's Disease | Tremor
Federal University of Uberlandia

Completed

Evaluation of the Six Minute Walk Test and Other Instruments in Heart Failure

Heart Failure | Quality of Life | Autonomic Nervous System Imbalance | Heart Rate and Rhythm Disorders

Brazil
Avid Radiopharmaceuticals

Completed

The Feasibility of Florbetapir Quantitation in Europe

Alzheimer's Disease

Netherlands
Jazz Pharmaceuticals

Recruiting

A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

Parkinson Disease | Tremor

United States, Spain, Germany, Poland
Markus Weber
University Hospital Inselspital, Berne; ETH Zurich

Not yet recruiting

Investigation of Cannabinoid 2-receptor Expression in the Brain and Spine of ALS-patients Compared to Healthy Controls With PET (18F-RoSMALS) (18F-RoSMALS)

Amyotrophic Lateral Sclerosis

Switzerland
NeurAxon Inc.

Completed

Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura

Migraine Without Aura

United States
British Columbia Cancer Agency

No longer available

18F-FDOPA PET in Neuroendocrine Tumours

Thyroid Cancer, Medullary | Neuroblastoma | Pheochromocytoma | Carcinoid Tumor | Paraganglioma | Insulinoma

Canada
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Study of Florbetapir (18F) in Japanese Healthy Volunteers

Alzheimer's Disease

Japan
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

Japan
Frederick Daniel Grant
Dana-Farber Cancer Institute

Completed

FLT-PET Imaging of Brain Tumors in Children

Brain Neoplasms

United States
Avid Radiopharmaceuticals

Withdrawn

Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians

Alzheimer's Disease

Japan
Chang Gung Memorial Hospital

Unknown

Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination (PMPBB3/AV45)

Alzheimer's Disease

Taiwan
Tammie L. S. Benzinger, MD, PhD

Withdrawn

F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

18F-AV-1451 High Resolution Autopsy Study

Alzheimer's Disease

United States
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Alzheimer's Disease

France, Italy, United States
ECOG-ACRIN Cancer Research Group

Not yet recruiting

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

Glioblastoma, IDH-Wildtype
CytomX Therapeutics

Terminated

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Solid Tumor | Unresectable or Metastatic Melanoma

Korea, Republic of, United States, Netherlands, Spain, Australia

Search clinical trials for: CX-188

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations